Tourmaline Oil Corp. (TSE:TOU – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twelve analysts that are covering the company, MarketBeat reports. Two analysts have rated ...
On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts ...
07, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of ...